Loading data
ACOGNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 10.22 m USD | — | — | — |
| Cost of revenue | 603.4 k USD | — | — | — |
| Research and development expense | 1.87 m USD | 3.92 m USD | 4.88 m USD | 8.72 m USD |
| Selling, general and administrative expense | 29.08 m USD | 8.01 m USD | — | — |
| Operating profit | -22.66 m USD | -12.01 m USD | -9.94 m USD | -13.56 m USD |
| Net income (reported basis) | -20.67 m USD | -14.79 m USD | -13.76 m USD | -12.07 m USD |
| Net income attributable to common shareholders | -20.67 m USD | -14.79 m USD | -13.76 m USD | — |
| Basic earnings per share | -1.17 USD/share | -2.04 USD/share | -3.84 USD/share | -4.44 USD/share |
| Diluted earnings per share | -1.18 USD/share | -2.04 USD/share | -3.84 USD/share | -4.44 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.